Home
CYTK
CYTK News

Latest Cytokinetics Incorporated (CYTK) News on June 3, 2025

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire

5 days ago

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

MT Newswires

5 days ago

Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating

Argus Research

14 days ago

CYTK: Rating increased to a HOLD

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

GlobeNewswire

16 days ago

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

18 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Simply Wall St.

18 days ago

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

GlobeNewswire

19 days ago

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Argus Research

21 days ago

CYTK: Lowering target price to $24.00

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

GlobeNewswire

21 days ago

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

GlobeNewswire

a month ago

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

MT Newswires

a month ago

B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating

Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a month ago

Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Cytokinetics to Hold Annual Meeting of Stockholders

GlobeNewswire

a month ago

Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

Zacks

a month ago

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

MT Newswires

a month ago

RBC Trims Price Target on Cytokinetics to $80 From $82, Keeps Outperform, Speculative Risk

Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges

GuruFocus.com

a month ago

Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges

Argus Research

a month ago

CYTK: Lowering target price to $27.00

MT Newswires

a month ago

Cytokinetics Q1 Net Loss Widens, Revenue Rises

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Zacks

a month ago

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

a month ago

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

Cytokinetics Inc (CYTK) Q1 2025: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

a month ago

Cytokinetics Inc (CYTK) Q1 2025: Everything You Need To Know Ahead Of Earnings

Why Cytokinetics, Inc. (CYTK) Went Down On Friday

Insider Monkey

a month ago

Why Cytokinetics, Inc. (CYTK) Went Down On Friday

MT Newswires

a month ago

Sector Update: Health Care Stocks Climb Late Afternoon

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

Benzinga

a month ago

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

MT Newswires

a month ago

Cytokinetics Shares Fall After FDA Extends Review of Heart Disease Treatment

MT Newswires

a month ago

UBS Adjusts Price Target on Cytokinetics to $41 From $47, Maintains Neutral Rating

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

BioPharma Dive

a month ago

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire

a month ago

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Participate in May Investor Conferences

GlobeNewswire

a month ago

Cytokinetics to Participate in May Investor Conferences

Argus Research

a month ago

CYTK: Lowering target price to $30.00

Cytokinetics to Announce First Quarter Results on May 6, 2025

GlobeNewswire

a month ago

Cytokinetics to Announce First Quarter Results on May 6, 2025

Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

TipRanks

a month ago

Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

MT Newswires

a month ago

Cytokinetics Insider Sold Shares Worth $769,200, According to a Recent SEC Filing

Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now?

Insider Monkey

2 months ago

Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now?

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

2 months ago

CYTK: Raising target price to $31.00

BMY Down on Heart Drug Camzyos Failure in Late-Stage Study

Zacks

2 months ago

BMY Down on Heart Drug Camzyos Failure in Late-Stage Study

Bristol Myers stumbles in bid to widen heart drug’s use

BioPharma Dive

2 months ago

Bristol Myers stumbles in bid to widen heart drug’s use

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

Investor's Business Daily

2 months ago

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

The Wall Street Journal

2 months ago

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Argus Research

2 months ago

CYTK: Lowering target price to $28.00

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Zacks

2 months ago

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Investor's Business Daily

2 months ago

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

Investopedia

2 months ago

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

Argus Research

2 months ago

CYTK: Lowering target price to $30.00

MT Newswires

2 months ago

Cytokinetics Insider Sold Shares Worth $611,250, According to a Recent SEC Filing

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

2 months ago

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy

Insider Monkey

2 months ago

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy

Argus Research

2 months ago

CYTK: Raising target price to $36.00

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey

2 months ago

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

Zacks

2 months ago

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

GlobeNewswire

2 months ago

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Cytokinetics Insider Sold Shares Worth $943,426, According to a Recent SEC Filing

MT Newswires

3 months ago

UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

GlobeNewswire

3 months ago

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

MT Newswires

3 months ago

Cytokinetics Insider Sold Shares Worth $1,080,750, According to a Recent SEC Filing

MT Newswires

3 months ago

Cytokinetics Insider Sold Shares Worth $374,900, According to a Recent SEC Filing

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Simply Wall St.

3 months ago

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)

Argus Research

3 months ago

CYTK: Lowering target price to $35.00

Cytokinetics to Participate in March Investor Conferences

GlobeNewswire

3 months ago

Cytokinetics to Participate in March Investor Conferences

Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

Zacks

3 months ago

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Cytokinetics Inc Earnings Call

MT Newswires

3 months ago

Oppenheimer Adjusts Price Target on Cytokinetics to $96 From $98, Maintains Outperform Rating

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses

GuruFocus.com

3 months ago

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Zacks

3 months ago

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Associated Press Finance

3 months ago

Cytokinetics: Q4 Earnings Snapshot

MT Newswires

3 months ago

Cytokinetics Q4 Net Loss Narrows, Revenue Rises

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

3 months ago

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

Cytokinetics Inc (CYTK) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

3 months ago

Cytokinetics Inc (CYTK) Q4 2024: Everything You Need To Know Ahead Of Earnings

Argus Research

3 months ago

CYTK: Raising target price to $37.00

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey

3 months ago

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now

Insider Monkey

3 months ago

Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

3 months ago

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

4 months ago

CYTK: Raising target price to $36.00

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

GlobeNewswire

4 months ago

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

MT Newswires

4 months ago

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Adjusts Price Target to $67 From $70

MT Newswires

4 months ago

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70

Cytokinetics Names Robert E. Landry to Board of Directors

GlobeNewswire

4 months ago

Cytokinetics Names Robert E. Landry to Board of Directors

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

Insider Monkey

4 months ago

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

MT Newswires

4 months ago

Citigroup Initiates Cytokinetics at Buy With $86 Price Target

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

4 months ago

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MT Newswires

4 months ago

B. Riley Adjusts Cytokinetics' Price Target to $88 From $92, Keeps Buy Rating

Argus Research

4 months ago

CYTK: What does Argus have to say about CYTK?

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Zacks

4 months ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

GlobeNewswire

4 months ago

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Zacks

4 months ago

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Argus Research

4 months ago

CYTK: Raising target price to $39.00

What Are Analysts Talking About Cytokinetics (CYTK)?

Insider Monkey

4 months ago

What Are Analysts Talking About Cytokinetics (CYTK)?

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Zacks

4 months ago

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Benzinga

4 months ago

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Argus Research

4 months ago

CYTK: Raising target price to $37.00

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

GlobeNewswire

4 months ago

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

Argus Research

5 months ago

CYTK: Lowering target price to $36.00

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

GlobeNewswire

5 months ago

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

5 months ago

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

5 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Share on Social Networks: